Business Wire

Oleg Burlakov, Leading Russian Entrepreneur, Self-Made Billionaire & Eco-Sailing Pioneer Dies At 72

Share

Oleg Burlakov Obituary:

Oleg Leonidovich Burlakov, a prominent Russian entrepreneur and leader in the industrial goods sector passed away on 21st June 2021 in Moscow aged 72 after a short battle with Covid-19.

Born in 1949 in St. Petersburg, Oleg was a Russian patriot, who in addition to business roles in the aerospace, chemicals and energy industries, is best known as the owner and visionary behind the Black Pearl, a trailblazing eco-sailing yacht which he commissioned in 2010.

Oleg is survived by his wife Lyudmila Burlakova and by his two daughters Veronica and Elena. The Burlakovs were married for 48 years, during which time the couple together built a considerable fortune.

Oleg had a series of very successful investments in Russia in the 80s and 90s across various sectors.

During his early career, Oleg was a member of the USSR air force who took immense pride in his military duties. In October 1988 he founded Integral, a co-operative active in the development of patents and scientific research for innovative chemical products that extended engine and battery life. His wife Lyudmila was among the list of members of the co-operative at its inception and helped to co-found the business alongside her husband. After initial successes with Integral, Oleg incorporated Sovinterfrance, a natural resources and mining company.

From 1992, Oleg invested in the oil industry and in the production of cement, by first taking control of one of the most important Russian national companies, Novoroscement, then subsequently the oil exploration company Burneftegaz. The takeovers commenced through Oleg’s Sovinterfrance. Through the sale of his cement business Novoroscement in 2007 for almost 1.5bn dollars and his gas business Burneftegaz in 2014 for around 1bn dollars, Oleg became a billionaire.

Beyond his enterprises in Russia, Oleg’s passion for sailing and the engineering and technology underpinning modern yachting has helped to cement his legacy. He was the visionary owner of the world’s second largest sailing yacht, the renowned 106.7-metre Oceanco eco-sailing yacht Black Pearl. The most defining feature of which is its three DynaRig carbon masts supporting a sail area of 2,900 square meters. By harnessing sail power, solar and a hybrid propulsion system that Oleg helped to bring to life, the Black Pearl is able to cross the Atlantic burning just 20 litres of fuel. Oleg is celebrated for his role in shaping the design and specifications of the Black Pearl and paving the way for yachts with sustainability and reduced carbon footprints in mind. The Black Pearl remains an enduring inspiration to the next generation of sailing yachts and is a testament to Oleg’s forward-looking engineering expertise.

Oleg and Lyudmila met when they were young students and had not yet made their fortune: Oleg reading aerospace engineering and Lyudmila pursuing a degree in aeronautical engineering. The couple’s ambition and business acumen enabled them to achieve success and build the family fortune.

They resided in Ukraine until 1993 before deciding to move together to the United States and then to Canada in 1995, where Oleg was laid to rest by his family on 16 July 2021 in the North York district.

The Burlakov family, Oleg’s wife, daughters and six grandchildren, welcome Mr. Burlakov’s friends and associates to join them in commemorating him and invite them to make contact should they wish to celebrate his life.

The Press Office of the Burlakov family and Lyudmila Burlakova

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media enquiries for the Burlakov family
Tancredi Intelligent Communication
burlakov1@tancredigroup.com
+44 7957 549 906 | +44 7449226720
Konstantin Dobrynin

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)18.9.2021 15:34:00 CEST | Press release

Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19. This marks the first time a monoclonal antibody treatment for COVID-19 has received a full approval to treat patients with COVID-19 from the Korean MFDS. In February, the Korean MFDS granted a Conditional Marketing Authorisation (CMA) for the emergency use of regdanvimab (CT-P59) and allowed the use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, high blood pressure) w

Ipsen: ESMO 2021: Cabometyx ® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer18.9.2021 06:30:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced presentation of new analyses at the European Society for Medical Oncology (ESMO) Congress 2021 across different forms of cancer for people treated with Cabometyx® (cabozantinib). Of note, the final analysis of the pivotal Phase III COSMIC-311 trial (Abstract LBA67) will be presented, with Cabometyx demonstrating a clinically meaningful, sustained efficacy benefit versus placebo in people living with previously treated radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). With a median follow-up of 10.1 months, Cabometyx continued to demonstrate superior median progression-free survival (mPFS) with a reduction in the risk of disease progression or death of 78% versus placebo (hazard ratio [HR]: 0.22, 96% confidence interval [CI]: 0.15-0.32; p<0.0001).1 This final analysis is consistent with data from the interim analysis, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021

Unifrax Hosts Groundbreaking Ceremony for SiFAB™ Manufacturing Line17.9.2021 20:46:00 CEST | Press release

Today, Unifrax, a leading manufacturer of high-performance specialty materials, held a ceremonial event celebrating its first large-scale SiFAB™ Silicon Fiber Anode Battery Technology manufacturing line, which is currently under construction at the company’s north central Indiana facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005495/en/ Unifrax team celebrates SiFAB groundbreaking at New Carlisle plant. (Photo: Business Wire) The event recognized Unifrax’s ongoing partnership with the State of Indiana and St. Joseph County, along with SiFAB’s continued progress. Unifrax executives, along with the SiFAB manufacturing team and local and state government officials, kicked off the ceremony at 10 a.m. EDT at the New Carlisle, IN plant, with remarks by John Dandolph, president and CEO, Unifrax. “Through the support of the State of Indiana and St. Joseph County, we have the ability to leverage our existing New Carli

Prince William announces 15 Finalists for inaugural year of the £50 million Earthshot Prize17.9.2021 19:01:00 CEST | Press release

The Earthshot Prize announces today its first-ever shortlist of 15 Finalists, each with a chance of winning £1million to support their innovative environmental solutions to the greatest challenges facing the planet. Prince William said: "Over half a century ago, President Kennedy’s ‘Moonshot’ programme united millions of people around the goal of reaching the moon. Inspired by this, The Earthshot Prize aims to mobilise collective action around our unique ability to innovate, problem solve and repair our planet. “I am honoured to introduce the 15 innovators, leaders, and visionaries who are the first ever Finalists for The Earthshot Prize. They are working with the urgency required in this decisive decade for life on Earth and will inspire all of us with their optimism in our ability to rise to the greatest challenges in human history.” Launched by Prince William and The Royal Foundation in October 2020, The Earthshot Prize is the most prestigious global environment prize in history. Li

Wipro Announces Co-innovation Space with Google Cloud17.9.2021 15:32:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the launch of the Wipro-Google Cloud Innovation Arena in Bangalore, India. This cloud collaboration space will provide in-house technical expertise, ensure seamless cloud adoption, and accelerate innovation to drive business transformation for customers. By combining the expertise and resources of Wipro FullStride Cloud Services and Google Cloud, this jointly developed innovation center will offer a unique combination of people, processes, and platforms that will collectively create a futuristic experience for customers globally. This state-of-the-art arena will showcase the talent, tools and best practices required to develop and deploy applications on Google Cloud. Jason Eichenholz, Senior Vice President, Global Head of Ecosystems & Partnerships, Wipro Limited said, “We are excited to strengthen our partnership with Google Clou

Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat17.9.2021 15:00:00 CEST | Press release

Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced today that ReVamp, an upcoming multiplayer social deception game, will launch soon in select markets exclusively for Snapchat. The vampire-themed game will be the first social deception title on Snapchat, giving Snapchatters their first chance to sink their teeth into this popular genre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005012/en/ Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat (Graphic: Business Wire) ReVamp is a real-time multiplayer imposter game where players aim to reveal who the vampire player is among their group of friends while they renovate the rooms of an old mansion. In the game, human players must complete renovation tasks, such as demolition and building, to improve their chances of survival while identifying and defeating the vampire during the voting phase. Vampire players mu

BeiGene Receives Positive CHMP Opinion for BRUKINSA ® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia17.9.2021 14:00:00 CEST | Press release

BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or first-line treatment for patients unsuitable for chemo-immunotherapy. “Bruton’s tyrosine kinase (BTK) inhibitors have emerged as a promising treatment for WM, yet treatment discontinuation due to lack of response or side effects remains a concern,” said Prof. Christian Buske, Medical Director at the University Hospital Ulm, Germany, and a trial investigator of the ASPEN study. “The ASPEN trial demonstrated that BRUKINSA provided deep and durable responses and offered substantial improvements in safety and tolerability over standard therapy. Patients in Europe with WM may soon have a new treatment option that can offer improved outcomes.